Phil Reilly is a venture partner at Third Rock Ventures, a respected clinical geneticist and a life science entrepreneur. He’s co-founded Fulcrum Therapeutics, Voyager Therapeutics, Edimer and Lotus Tissue Repair and served as interim CMO at bluebird bio and Goldfinch Bio.
Phil is a trustee emeritus of Cornell University, is an overseer of Weill Cornell Medical College, and serves on the advisory board to the Boston University School of Public Health. Previously Phil was the CEO of Interleukin Genetics, and before that, he was the executive director of the Eunice Kennedy Shriver Center for Mental Retardation. He served twice (2000 and 2003) as president of the American Society of Law, Medicine and Ethics. He is a founding fellow of the American College of Medical Genetics. He has authored or co-authored more than 100 articles in scholarly journals and has published seven books including most recently Orphan: The Quest to Save Children with Rare Genetic Disorders. Phil has held teaching positions at Tufts University School of Medicine and Harvard Medical School.
He received his undergraduate degree from Cornell University and holds a medical degree from Yale University, a law degree from Columbia University, is a member of the Massachusetts Bar and is board certified in internal medicine and clinical genetics.